Other CAR constructs, such as CAR-T cells against CD30 (CAR-T-30), have been used to treat to treat Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), which do not express CD19. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.